Growing body of evidence
Agendia’s extensive clinical trials and research collaborations have produced numerous retrospective and prospective validation studies over the past decade further supporting the prognostic and predictive ability of MammaPrint and BluePrint for early stage breast cancer patients. In addition, large, multi-institutional clinical trials, such as MINDACT and ISPY-2, can be expected to expand the assay’s clinical importance and indications for use. In the first ever phase III, prospective, randomized study for a breast cancer recurrence assay, the five year results of the Microarray In Node-negative (or 1-3 positive lymph node) Disease may Avoid ChemoTherapy (MINDACT) clinical trial showed 46% of clinically high risk patients were genomically Low Risk and showed no statistical benefit to chemotherapy.
With Agendia’s state-of-the-art molecular diagnostic laboratories in California and the Netherlands, the company is actively engaging academic centers, medical institutions and pharmaceutical companies in clinical trials collaboration opportunities, globally.
Currently, Agendia is enrolling institutions and cancer centers worldwide in the following studies: